Pharmacotherapeutics for Advanced Practice- A Practical Approach 5th Edition Arcangelo Test Bank LATEST

PHARMACOTHERAPEUTICSnFORnADVANCEDnPRACTICEnNURSEnPRESCRIBERS,QUESTIONSn&nANS
WERSnFULLYnANALYSEDnEDITIONnEXAMn100%nCORRECTLY/VERIFIEDnANSWERSnWITHnSATISFAC
TIONnGUARANTEEDnSUCCESSnLATESTnUPDATEn2023/2024n5THnEDITIONnWOOnROBINSONnTESTnBANK
nGRADEDnA+



Chapter 1. n n



An Introduction to Pharmacogenetics
n n n


Multiple Choice n


Identify the choice that best completes the statement or answers the question.
n n n n n n n n n n n




n 1. Genetic polymorphisms account for differences in metabolism, including:
nnnn n n n n n n n n


1. Poor metabolizers, who lack a working enzyme
n n n n n n


2. Intermediate metabolizers, who have one working, wild-type allele and one mutant
n n n n n n n n n n


3. Extensive metabolizers, with two normally functioning alleles
n n n n n n


4. All of the above n n n




n 2. Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
nnnn n n n n n n n n n n n


1. A need to monitor drugs metabolized by 2D6 for toxicity
n n n n n n n n n


2. Increased dosages needed of drugs metabolized by 2D6, such as the s
n n n n n n n n n n n


elective serotoreuptake inhibitors n n n


3. Decreased conversion of codeine to morphine by CYP 2D6 n n n n n n n n


4. The need for lowered dosages of drugs, such as beta blockers
n n n n n n n n n n




n 3. Rifampin is a nonspecific CYP450 inducer that may:
nnnn n n n n n n n n


1. Lead to toxic levels of rifampin and must be monitored closely
n n n n n n n n n n


2. Cause toxic levels of drugs, such as oral contraceptives, when coadministered
n n n n n n n n n n


3. Induce the metabolism of drugs, such as oral contraceptives, leading to therapeutic
n n n n n n n n n n n


4. Cause nonspecific changes in drug metabolism
n n n n n




n 4. Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
nnnn n n n n n n n n n n n n


1. Decreased therapeutic levels of quinidine n n n n


2. Increased therapeutic levels of quinidine n n n n


3. Decreased levels of a coadministered drug, such as digoxin, that req
n n n n n n n n n n


uires P-glycoprabsorption and elimination
n n n n


4. Increased levels of a coadministered drug, such as digoxin, that requ
n n n n n n n n n n


ires P-glycoproabsorption and elimination
n n n n




n 5. Warfarin resistance may be seen in patients with VCORC1 mutation, leading to:
nnnn n n n n n n n n n n n n


1. Toxic levels of warfarin building up
n n n n n


2. Decreased response to warfarin n n n

,PHARMACOTHERAPEUTICSnFORnADVANCEDnPRACTICEnNURSEnPRESCRIBERS,QUESTIONSn&nANS
WERSnFULLYnANALYSEDnEDITIONnEXAMn100%nCORRECTLY/VERIFIEDnANSWERSnWITHnSATISFAC
TIONnGUARANTEEDnSUCCESSnLATESTnUPDATEn2023/2024n5THnEDITIONnWOOnROBINSONnTESTnBANK
nGRADEDnA+


3. Increased risk for significant drug interactions with warfarin
n n n n n n n


4. Less risk of drug interactions with warfarin
n n n n n n



n

6. Genetic testing for VCORC1 mutation to assess potential warfar
nnnn n n n n n n n n n


in resistance is requiredprior to prescribing warfarin.
n n n n n n n


1. True
2. False
n

7. Pharmacogenetic testing is required by the U.S. Food and Drug
nnnn n n n n n n n n n n n


Administration prior toprescribing:
n n n


1. Erythromycin
2. Digoxin
3. Cetuximab

,PHARMACOTHERAPEUTICSnFORnADVANCEDnPRACTICEnNURSEnPRESCRIBERS,QUESTIONSn&nANS
WERSnFULLYnANALYSEDnEDITIONnEXAMn100%nCORRECTLY/VERIFIEDnANSWERSnWITHnSATISFAC
TIONnGUARANTEEDnSUCCESSnLATESTnUPDATEn2023/2024n5THnEDITIONnWOOnROBINSONnTESTnBANK
nGRADEDnA+


4. Rifampin
n

8. Carbamazepine has a Black Box Warning recommending testing fo
nnnn n n n n n n n n n


r the HLA-
n n


B*1502 allelein patients with Asian ancestry prior to starting therapy due
n n n n n n n n n n n


to:
n


1. Decreased effectiveness of carbamazepine in treating seizures in Asian patients wit
n n n n n n n n n n


HLA-B*1502 allele n


2. Increased risk for drug interactions in Asian patients with the HLA-B*1502 allele
n n n n n n n n n n n


3. Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-B*1502 a
n n n n n n n n n n


4. Patients who have the HLA- n n n n


B*1502 allele being more likely to have a resistance tocarbamazepi
n n n n n n n n n n


ne
n

9. A genetic variation in how the metabolite of the cancer dru
nnnn n n n n n n n n n n n


g irinotecan SN-38 isinactivated by the body may lead to:
n n n n n n n n n n


1. Decreased effectiveness of irinotecan in the treatment of cancer
n n n n n n n n


2. Increased adverse drug reactions, such as neutropenia
n n n n n n


3. Delayed metabolism of the prodrug irinotecan into the active metabolite SN-38
n n n n n n n n n n


4. Increased concerns for irinotecan being carcinogenic
n n n n n




n 10. Patients who have a poor metabolism phenotype will have:
nn n n n n n n n n n


1. Slowed metabolism of a prodrug into an active drug, leading to accumulation of pr
n n n n n n n n n n n n n


2. Accumulation of inactive metabolites of drugs n n n n n


3. A need for increased dosages of medications
n n n n n n


4. Increased elimination of an active drug n n n n n




n 11. Ultra-rapid metabolizers of drugs may have:
nn n n n n n n


1. To have dosages of drugs adjusted downward to prevent drug accumulation
n n n n n n n n n n


2. Active drug rapidly metabolized into inactive metabolites, leading to
n n n n n n n n


potential therafailure
n n n


3. Increased elimination of active, nonmetabolized drug
n n n n n


4. Slowed metabolism of a prodrug into an active drug, leading to an accumulation of
n n n n n n n n n n n n n



n

12. A provider may consider testing for CYP2D6 variants prior t
nn n n n n n n n n n n

, PHARMACOTHERAPEUTICSnFORnADVANCEDnPRACTICEnNURSEnPRESCRIBERS,QUESTIONSn&nANS
WERSnFULLYnANALYSEDnEDITIONnEXAMn100%nCORRECTLY/VERIFIEDnANSWERSnWITHnSATISFAC
TIONnGUARANTEEDnSUCCESSnLATESTnUPDATEn2023/2024n5THnEDITIONnWOOnROBINSONnTESTnBANK
nGRADEDnA+


o starting tamoxifen forbreast cancer to:
n n n n n n


1. Ensure the patient will not have increased adverse drug reactions to the tamoxifen
n n n n n n n n n n n n


2. Identify potential drug-drug interactions that may occur with tamoxifen
n n n n n n n n


3. Reduce the likelihood of therapeutic failure with tamoxifen treatment
n n n n n n n n


4. Identify poor metabolizers of tamoxifen
n n n n